Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.

Publication date: Nov 12, 2024

Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels at 4 weeks post-Ad26. COV2. S vaccination as correlates of risk and of protection against severe-critical COVID-19 through 220 days post-vaccination in the ENSEMBLE trial (NCT04505722), constituting ~4. 5 months longer follow-up than our previous correlates analysis and enabling inclusion of 42 severe-critical vaccine-breakthrough cases. Neutralizing antibody titer is a strong inverse correlate of severe-critical COVID-19, with estimated hazard ratio (HR) per 10-fold increase 0. 35 (95% CI: 0. 13, 0. 90). In a multivariable model, HRs are 0. 31 (0. 11, 0. 89) for neutralizing antibody titer and 1. 22 (0. 49, 3. 02) for anti-Spike binding antibody concentration. VE against severe-critical COVID-19 rises with neutralizing antibody titer: 63. 1% (95% CI: 40. 0%, 77. 3%) at unquantifiable [

Open Access PDF

Concepts Keywords
Covid Ad26COVS1
Hrs Ad26COVS1
Nct04505722 Adult
Vaccine Aged
Antibodies, Neutralizing
Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Humans
Male
Middle Aged
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
Vaccination
Vaccine Efficacy

Semantics

Type Source Name
disease MESH COVID-19

Original Article

(Visited 3 times, 1 visits today)